<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Between February 1992 and November 1996 we treated 30 newly diagnosed <z:hpo ids='HP_0011009'>acute</z:hpo> promyelocytic <z:mpath ids='MPATH_336'>leukaemia</z:mpath> (APL) patients either with oral <z:hpo ids='HP_0000001'>all</z:hpo>-trans-<z:chebi fb="2" ids="26536">retinoic acid</z:chebi> (ATRA) alone (45 mg m-2) or with a simultaneous combination of ATRA (45 mg m-2), <z:chebi fb="0" ids="41977">daunorubicin</z:chebi> (DNR, 50 mg/m-2 for 3 days) and <z:chebi fb="1" ids="16040">cytosine</z:chebi> <z:chebi fb="0" ids="22601">arabinoside</z:chebi> (ARA-C, 200 mg m-2 for 7 days) </plain></SENT>
<SENT sid="1" pm="."><plain>There were 15 patients in each group </plain></SENT>
<SENT sid="2" pm="."><plain>Patients with a white blood cell count &lt; 5 x 10(9)/l at diagnosis received only ATRA as an induction therapy </plain></SENT>
<SENT sid="3" pm="."><plain>Patients with initial white blood cell count &gt; 5 x 10(9)/l received a combination of ATRA, DNR and ARA-C as an induction therapy </plain></SENT>
<SENT sid="4" pm="."><plain>Within the first 20 days of induction, there were two early <z:hpo ids='HP_0011420'>deaths</z:hpo> in the group of patients receiving only ATRA, and six early <z:hpo ids='HP_0011420'>deaths</z:hpo> in the group of patients treated with a combination of ATRA and chemotherapy </plain></SENT>
<SENT sid="5" pm="."><plain>Ten out of 13 patients (76.9%) receiving ATRA only achieved complete remission (CR) whereas seven out of nine patients (77.8%) receiving ATRA with chemotherapy achieved CR </plain></SENT>
<SENT sid="6" pm="."><plain>Initial median peripheral white blood cell counts were significantly lower in the group of patients treated with ATRA alone (2.3 x 10(9)/l) than in the group of patients receiving ATRA and chemotherapy (14.0 x 10(9)/l) </plain></SENT>
<SENT sid="7" pm="."><plain>Morphological evidence of differentiation was noted in <z:hpo ids='HP_0000001'>all</z:hpo> patients entering CR </plain></SENT>
<SENT sid="8" pm="."><plain>Patients in both groups who achieved CR received one course of standard '3 + 7' chemotherapy (DNR 45 mg m-2, 1-3 days, ARA-C 200 mg m-2, 1-7 days) followed by two courses of standard '2 + 5' chemotherapy (DNR 50 mg m-2 1-2 days, ARA-C 200 mg m-2 1-5 days) as a consolidation therapy </plain></SENT>
<SENT sid="9" pm="."><plain>Patients not achieving remission (three out of 13 in the ATRA group and two out of nine in ATRA+chemotherapy group) did not respond to salvage chemotherapy and <z:hpo ids='HP_0000001'>all</z:hpo> died within 3 months of diagnosis </plain></SENT>
<SENT sid="10" pm="."><plain>Only one out of 10 patients (10%) in CR, treated with ATRA is in relapse after 18 months </plain></SENT>
<SENT sid="11" pm="."><plain>In patients treated with ATRA alone two out of 10 (20%) survived 58 months following diagnosis whereas in the ATRA+chemotherapy group one out of seven has already survived their 58th month since diagnosis </plain></SENT>
<SENT sid="12" pm="."><plain>Four out of eight patients with an early <z:hpo ids='HP_0011420'>death</z:hpo> died of <z:chebi fb="2" ids="26536">retinoic acid</z:chebi> syndrome </plain></SENT>
<SENT sid="13" pm="."><plain>Other toxicities due to ATRA were minimal (<z:hpo ids='HP_0100825'>cheilitis</z:hpo>, <z:hpo ids='HP_0000958'>xerosis</z:hpo>, <z:hpo ids='HP_0000964'>dermatitis</z:hpo>, diarrhoea, liver damage or <z:e sem="disease" ids="C0033845" disease_type="Disease or Syndrome" abbrv="">pseudotumor cerebri</z:e>) </plain></SENT>
</text></document>